Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2020 16:17 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 23, 2020 07:00 ET | Source: Selecta Biosciences, Inc.

First Patient Randomized in the Phase 3 DISSOLVE Clinical Program of SEL-212 for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the...
September 08, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
September 01, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Secures Up To $35 Million Debt Financing with Oxford Finance LLC and Silicon Valley Bank

WATERTOWN, Mass., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 06, 2020 07:30 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Updates

Closed strategic licensing agreement with Sobi for SEL-212 for $100 million in initial payments and up to $630 million in potential milestones, and tiered double-digit royaltiesEntered into research...
August 03, 2020 16:05 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences Appoints Peter G. Traber, MD as Chief Medical Officer

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
August 03, 2020 08:15 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 30, 2020 08:00 ET | Source: Selecta Biosciences, Inc.

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter Financial Results and Recent Operational Highlights

WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...
July 28, 2020 06:00 ET | Source: Selecta Biosciences, Inc.

Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

STOCKHOLM, Sweden and WATERTOWN, Mass., July 28, 2020 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced that the strategic licensing agreement with Selecta...
June 18, 2020 08:30 ET | Source: Selecta Biosciences, Inc.

Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases

CAMBRIDGE, Mass. and WATERTOWN, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, and Selecta Biosciences,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right